Introduction: Tuberculosis is the leading cause of death from infectious disease. Current
drug therapy requires a combination of antibiotics taken over> 6 months. An urgent need for …

In drug development, there are typically a series of preclinical studies that must be
completed with new compounds or regimens before use in humans. A sequence of in vitro …

Objectives The intracellularly surviving and slow-growing pathogen, Mycobacterium
tuberculosis, adapts the host cell environment for its active and dormant life cycle. It is …

The objective of this study was to measure the efficacy of Mycobacterium smegmatis as a
surrogate in vitro model for the detection of compounds which are inhibitory to the growth of …

The continuing global epidemic of tuberculosis, the increasing rate of multidrug resistant
(MDR) tuberculosis and the more recent emergence of extensively drug resistant (XDR) …

Murine models of M ycobacterium tuberculosis infection are essential tools in drug
discovery. Here we describe a fast standardized 9-day acute assay intended to measure the …

The assessment of physiochemical and pharmacological properties at early stages of drug
discovery can accelerate the conversion of hits and leads into candidates for further …

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a leading cause of
morbidity and mortality worldwide. With the increased spread of multi drug-resistant TB …

New drugs that retain potency against multidrug/extensively drug-resistant strains of
Mycobacterium tuberculosis, with the additional benefit of a shortened treatment duration …

Tuberculosis (TB) caused by Mycobacterium tuberculosis continues being a big public
health problem around the world. The total number of cases of TB worldwide in 2009 was …